Skip to content
DataLookout
Menu

NCT02269150

Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 22 versions: 13 with changes below, 9 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Oct 2026 to Oct 2027
    • Eligibility criteria expanded, about 4 words
    • Publications: details revised at 1 of 1 entry
  2. Notable Primary and study completion dates: Oct 2025 to Oct 2026v21
  3. Notable Primary and study completion dates: Oct 2023 to Oct 2025v18
  4. Notable Primary and study completion dates: Oct 2022 to Oct 2023v17
  5. Notable Primary and study completion dates: Oct 2021 to Oct 2022v15
Show 7 earlier versionsHide 7 earlier versions
  1. Notable Primary and study completion dates: Oct 2020 to Oct 2021v14
  2. Notable Primary and study completion dates: Oct 2019 to Oct 2020v13
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 96 to confirmed 59
    • Site details revised
    v12
  4. Notable Primary and study completion dates: Oct 2018 to Oct 2019v11
  5. Notable Primary completion date: Oct 2017 to Oct 2018
    • Eligibility criteria shortened, about 3 words
    • Study completion date: Oct 2018
    • Study description expanded, about 4 words
    v10
  6. Notable Eligibility criteria expanded, about 21 words
    • Study description expanded, about 11 words
    v7
  7. Minor Study description shortened, about 1 wordv5
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Clostridium difficile infection (CDI)
Timeframe: up to 1 year following randomization

Arms and interventions

Fecal microbiota transplantation with pre-transplant fecesExperimental

Prior to transplant hospitalization, store feces for testing and possible future use. Patients undergo fecal microbiota transplantation with the subject's stored pre-transplantation feces. The post-engraftment Bacteroidetes testing, randomization, and fecal microbiota transplantation procedure should all be performed within a 28-day window, beginning on the first day of engraftment. In the event that engraftment occurs prior to day +7, the 28-day window will start on day +7. Subjects from both arms will be followed for one year after transplantation for development of CDI, which will be treated by their BMT clinicians per the standards of care at MSKCC. Subjects from both arms will also be assessed for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially, if feasible, until one year post randomization and analyzed for microbial diversity and composition.

No FMT, routine managementActive comparator

Subjects from both arms will be followed for one year after randomization for development of CDI, which will be treated by their primary BMT clinician per the standards of care at MSKCC. Subjects from both arms will also be assessed by their BMT clinicians for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially if feasible until one year post randomization and analyzed for microbial diversity and composition.

Biologicals: fecal microbiota transplantation (FMT)

Other: No fecal microbiota transplantation (FMT), routine management

Sites

1 site in 1 country

  • Memorial Sloan Kettering Cancer CenterNew York, New York, United States